← brief for 2026-10-21 · Slowing decline

Combination finerenone and empagliflozin for chronic kidney disease with type 2 diabetes: a target trial emulation

Article C Peer reviewed Observational

Key takeaways

Researchers looked at records from three hospitals in China. They compared people taking two kidney-protecting drugs together against people taking just one. The group taking both drugs had less protein in their urine. This shows a link, but it is not proof that the combination causes the benefit.

Who did this work

Lei Li (Chengdu University of Traditional Chinese Medicine) · Dan Zhang (Chengdu University of Traditional Chinese Medicine) · Manrong Xu (Shanghai Jiao Tong University) · Shaohua Li (Army Medical University) · Yun Shen (Pennington Biomedical Research Center) · Shengdi Lu (Pennington Biomedical Research Center)

Source

Article · OpenAlex, CKD works · 2026-10-20
https://doi.org/10.3389/fneph.2026.1930977